Subsidy Information and Financing Scheme MSHLPemigatinib (Pemazyre) Tablet 4.5 mg, 9 mg, 13.5 mg Treatment of patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or... See all × MSHLPemigatinib (Pemazyre) Tablet 4.5 mg, 9 mg, 13.5 mg Treatment of patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.